New Study Identifies Challenges for COVID-19 Vaccine Adoption

▴ New Study Identifies Challenges for COVID-19 Vaccine Adoption
Advisory firm Avenue Group® conducted a series of one-on-one, in-depth phone interviews with doctors, nurses, and members of the general public to better understand what needs to happen in order for Americans to feel comfortable choosing to take a COVID-19 vaccine.

Advisory firm Avenue Group® conducted a series of one-on-one, in-depth phone interviews with doctors, nurses, and members of the general public to better understand what needs to happen in order for Americans to feel comfortable choosing to take a COVID-19 vaccine.

The World Health Organization estimates that 65 to 75 percent of the population well over 200 million Americans need to have antibodies either by means of a vaccine or through recovery from the virus to reach herd immunity. Last month, Dr. Anthony Fauci said, "We know what the efficacy of the vaccines is, but its effectiveness will depend on how many people take the vaccine."

Avenue Group's research identified several areas that need to be addressed to increase the vaccination adoption rate. Avenue Group Founder Jeremy Greenberg said, "Only half of the participants told us that they are likely to take a COVID-19 vaccine. Vaccine safety and side effects are viewed as the most important factors driving the vaccination decision. Two-thirds of those not likely to take the vaccine doubt the safety of it. These are concerning issues that need to be addressed by policy leaders and health experts."

Several concerning themes emerged from Avenue Group's interviews: women are more often the gatekeepers for households and are less likely to take a COVID-19 vaccine than men, over one-third of doctors and nurses are not yet supportive of taking a vaccine, and some do not consider their doctor's recommendation important and are leery of new vaccines.

There were encouraging themes as well. President-elect Joe Biden's victory had a net positive impact on vaccination adoption. Half of Biden voters said that Biden's forthcoming oversight of distribution makes them more likely to take it, while Trump voters said that their vaccine decision is unaffected by who is president. Older and high-risk participants were more likely to take the vaccine. A 74-year-old retired participant from Port St. Lucie, Florida, said, "It makes sense for me. I'm older and I have a low immune system."

About the Study:

Avenue Group conducted confidential one-on-one interviews over the phone between November 13-23, 2020, during a surge in coronavirus cases across the U.S., and, after President-elect Joe Biden had been declared the winner of the presidential election. The average interview length was 30 minutes. The 40 participants in the study included 17 individuals from the medical community (11 doctors, six nurses) and 23 members of the general public.

The findings from this small study should be considered directional as this was not a large population study, and we prioritized deeper, live interactions over sample size. Participants constituted a diverse representation of American society, across gender, race, income, geography, employment status, level of education, political affiliation, and other demographic factors.

About Avenue Group: Avenue Group® advises private equity firms, Fortune 500s, mid-market companies, and non-profits. The company combines data with a firsthand narrative to drive smarter decisions with a primary research-first approach. Avenue Group sources conduct and analyze in-depth interviews and surveys to develop meaningful actionable insights for clients. The firm generates real-time market feedback to move beyond existing data and industry stereotypes.

Tags : #NewYork #America #AvenueGroup #WHO #Covid19 #Covid19VAccine #DrAnthonyFauci #FightAgainstVirus #Vaccination

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

In a Miraculous Recovery a 13-Year-Old Girl in Delhi Awakens from Coma After Liver Transplant.May 21, 2024
Tackling Hypertension in South-East Asia: A Call to Action on World Hypertension DayMay 20, 2024
FSSAI's Crackdown on Harmful Fruit Ripening Practices: Ensuring Public Health and ComplianceMay 20, 2024
Uncovering the Presence of Microplastics in Human Blood and Their Health EffectsMay 18, 2024
Potential Risks of Meftal: What Consumers and Doctors Should KnowMay 18, 2024
Over-the-Counter Medications in India: A New Era of AccessibilityMay 18, 2024
DCGI Acts Against Overcharging: New Regulations for Blood CentresMay 17, 2024
Cattle as Hosts for Human and Bird Flu Viruses: A Potential Public Health ConcernMay 17, 2024
The Ethics of Live Surgery Broadcasts: NMC Seeks Public OpinionMay 17, 2024
Successful Removal of 3.7 KG Large Abdominal Tumor from 14-Year-Old Somalian Girl at KIMS Cuddles HospitalMay 16, 2024
iLEAD Sets a Precedent by Launching a Graphic Anthology Authored by Multimedia, Animation and Graphics Students May 16, 2024
Ramaiah Memorial Hospital Launches Novel Intra-Operative Radiation Therapy (IORT); Achieves significant advancement in Cancer Treatment to Enhance Quality of LifeMay 16, 2024
IIITH Announces Product Management Summer SchoolMay 16, 2024
Çelebi India's Delhi Cargo Terminal Successfully Handles Airbus H125 Helicopter ShipmentMay 16, 2024
Plant-Based Diets and Prostate Cancer: New UCSF Study Shows Promising ResultsMay 16, 2024
National Medical Commission Approves 112 New Medical CollegesMay 16, 2024
Study Suggests That Chemotherapy Results in Physical Decline for Older Women with Breast CancerMay 16, 2024
Google DeepMind's AlphaFold 3: Revolutionizing Drug Discovery with AIMay 16, 2024
Hester Biosciences Ltd reports Consolidated Revenue growth of 18% at Rs. 79.3 crore, EBITDA up 37% to Rs. 16.4 crore and Net Profit up 12% to Rs. 6.40 crore in Q4FY24May 16, 2024
Akshay Tritiya Parna Mahotsav heldMay 16, 2024